Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thrombin receptor antagonists

S M Seiler1

  • 1Department of Cardiovascular Biochemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543, USA.

Seminars in Thrombosis and Hemostasis
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tuberculin skin testing of physicians at a midwestern teaching hospital: a 6-year prospective study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2001
Same author

Solid-phase synthesis of benzisothiazolones as serine protease inhibitors.

Bioorganic & medicinal chemistry letters·1999
Same author

Management and outcome of tuberculosis in two St Louis hospitals, 1988 to 1994.

Infection control and hospital epidemiology·1998
Same author

1,2-Benzisothiazol-3-one 1,1-dioxide inhibitors of human mast cell tryptase.

Journal of medicinal chemistry·1998
Same author

[3-[4-(4,5-Diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid (BMY 45778) is a potent non-prostanoid prostacyclin partial agonist: effects on platelet aggregation, adenylyl cyclase, cAMP levels, protein kinase, and iloprost binding.

Prostaglandins·1997
Same author

Development of potent thrombin receptor antagonist peptides.

Journal of medicinal chemistry·1996
Same journal

Full- vs Reduced-Dose Direct Oral Anticoagulants for Extended Treatment of Cancer-Associated Thrombosis: A Multicenter Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026
Same journal

Too Old for PESI?: Risk Stratification of Octogenarians with Pulmonary Embolism in the Emergency Department.

Seminars in thrombosis and hemostasis·2026
Same journal

Acute Management and Bleeding Outcomes in Pediatric Pulmonary Embolism: A Large Single-Center Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026
Same journal

Red Blood Cells in Hemostasis and Thrombosis: Mechanisms, Interactions, and Clinical Implications.

Seminars in thrombosis and hemostasis·2026
Same journal

Pediatric Pulmonary Infarction and Infarction-Like Pulmonary Injury: An Etiology-Oriented Narrative Review.

Seminars in thrombosis and hemostasis·2026
Same journal

Comparison of the Coagulation Profile Following Treatment of Major Surgical Haemorrhage with Fresh Frozen Plasma or Fibrinogen Concentrate.

Seminars in thrombosis and hemostasis·2026
See all related articles

Thrombin receptor antagonists offer a selective approach to antithrombotic therapy. Further research is needed to develop potent compounds for effective treatment of thrombosis and atherosclerosis.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Cardiovascular Research

Background:

  • Thrombin receptor is crucial for platelet activation and vascular smooth muscle proliferation.
  • The receptor's presence in atherosclerotic plaques suggests its role in thrombosis and atherosclerosis.
  • Thrombin receptor antagonists may offer greater selectivity than active site inhibitors in antithrombotic therapy.

Purpose of the Study:

  • To explore the potential of thrombin receptor antagonists in antithrombotic therapy.
  • To investigate the structural requirements for thrombin receptor activation.
  • To synthesize and evaluate peptide-based thrombin receptor antagonists.

Main Methods:

  • Utilizing blocking antibodies to study thrombin receptor function in vitro and in vivo.

Related Experiment Videos

  • Conducting amino acid substitution studies to understand receptor activation.
  • Synthesizing peptide-based agonists and antagonists.

    • Main Results:

    • Blocking antibodies implicated the thrombin receptor in cellular actions and arterial thrombosis models.
    • Structural requirements for receptor activation by peptides were identified.
    • Current peptide-based antagonists show limited potency and some act as partial agonists.

    Conclusions:

    • Thrombin receptor antagonists hold promise for selective antithrombotic therapy.
    • Further development is required to overcome potency limitations of current antagonists.
    • More potent compounds are expected from ongoing investigations for clinical evaluation.